Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Interferon-Alpha-2b in Metastatic Melanoma
NCT00026221Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2001
- Primary completion
- Nov 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in melanoma, sponsored by National Cancer Institute. Started Nov 2001; status: completed.
02
Drugs
bevacizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00026221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026221.